PURPOSE: In pediatric oncology, Wilms' tumor and advanced neuroblastoma represent opposite ends of the spectra of survival probability and therapeutic intensity. Consequently, it was envisaged that survivors of Wilms' tumor would enjoy better health status and health-related quality of life (HRQL) than survivors of advanced neuroblastoma. PATIENTS AND METHODS: Health status questionnaires were sent to the parents of all eligible children and to the children themselves if they were > or = 8 years of age. Responses were received from 84% of 93 eligible families. Responses were converted by established algorithms into levels of two multiattribute health status classification systems known as Health Utilities Index Mark 2 and Mark 3. These systems are linked to measures of preference, in the form of multiattribute utility functions, which provide scores of morbidity for single-attribute levels and of global HRQL for comprehensive health states. RESULTS: A greater burden of morbidity was identified in the survivors of advanced neuroblastoma than in survivors of Wilms' tumor based on the assessments of the parents of these children. In particular, survivors of advanced neuroblastoma exhibited deficits in hearing and speech. It is possible that this morbidity burden reflects the prevalent use of platinum compounds (causing ototoxicity) in this group. Within parent-child dyads there was a high level of percentage agreement on responses in all attributes except cognition. CONCLUSION: Extension of this study to a larger sample size of patients will provide clarification of these observations.
PURPOSE: In pediatric oncology, Wilms' tumor and advanced neuroblastoma represent opposite ends of the spectra of survival probability and therapeutic intensity. Consequently, it was envisaged that survivors of Wilms' tumor would enjoy better health status and health-related quality of life (HRQL) than survivors of advanced neuroblastoma. PATIENTS AND METHODS: Health status questionnaires were sent to the parents of all eligible children and to the children themselves if they were > or = 8 years of age. Responses were received from 84% of 93 eligible families. Responses were converted by established algorithms into levels of two multiattribute health status classification systems known as Health Utilities Index Mark 2 and Mark 3. These systems are linked to measures of preference, in the form of multiattribute utility functions, which provide scores of morbidity for single-attribute levels and of global HRQL for comprehensive health states. RESULTS: A greater burden of morbidity was identified in the survivors of advanced neuroblastoma than in survivors of Wilms' tumor based on the assessments of the parents of these children. In particular, survivors of advanced neuroblastoma exhibited deficits in hearing and speech. It is possible that this morbidity burden reflects the prevalent use of platinum compounds (causing ototoxicity) in this group. Within parent-child dyads there was a high level of percentage agreement on responses in all attributes except cognition. CONCLUSION: Extension of this study to a larger sample size of patients will provide clarification of these observations.
Authors: P S Hinds; J S Gattuso; A Fletcher; E Baker; B Coleman; T Jackson; A Jacobs-Levine; D June; S N Rai; S Lensing; C H Pui Journal: Qual Life Res Date: 2004-05 Impact factor: 4.147
Authors: Marten J Poley; Werner B F Brouwer; Jan J V Busschbach; Frans W J Hazebroek; Dick Tibboel; Frans F H Rutten; Jan C Molenaar Journal: Pediatr Surg Int Date: 2007-11-06 Impact factor: 1.827
Authors: Lisa Pogany; Ronald D Barr; Amanda Shaw; Kathy N Speechley; Maru Barrera; Elizabeth Maunsell Journal: Qual Life Res Date: 2006-02 Impact factor: 4.147
Authors: Qian Lu; Kevin R Krull; Wendy Leisenring; Jason E Owen; Toana Kawashima; Jennie C I Tsao; Bradley Zebrack; Ann Mertens; Gregory T Armstrong; Marilyn Stovall; Leslie L Robison; Lonnie K Zeltzer Journal: Pain Date: 2011-09-09 Impact factor: 6.961
Authors: Anne F Klassen; Samantha J Anthony; Aalia Khan; Lillian Sung; Robert Klaassen Journal: Support Care Cancer Date: 2011-05-25 Impact factor: 3.603
Authors: Daniel Stark; Abby R Rosenberg; Donna Johnston; Kristin Knight; Lizzie Caperon; Elizabeth Uleryk; A Lindsay Frazier; Lillian Sung Journal: J Speech Lang Hear Res Date: 2016-10-01 Impact factor: 2.297
Authors: Cheryl L Cox; Shelly Lensing; Shesh N Rai; Pam Hinds; Elizabeth Burghen; Ching-Hon Pui Journal: Qual Life Res Date: 2005-05 Impact factor: 4.147
Authors: Wendy Landier; Kristin Knight; F Lennie Wong; Jin Lee; Ola Thomas; Heeyoung Kim; Susan G Kreissman; Mary Lou Schmidt; Lu Chen; Wendy B London; James G Gurney; Smita Bhatia Journal: J Clin Oncol Date: 2014-01-13 Impact factor: 44.544